<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Ocular</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Daewoong takes over Turn Bio’s longevity platform from Hanall</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731469</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731469-daewoong-takes-over-turn-bios-longevity-platform-from-hanall</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-aging-time.webp?t=1693406596" type="image/jpeg" medium="image" fileSize="349155">
        <media:title type="plain">DNA double helix with sand hour glass</media:title>
      </media:content>
    </item>
    <item>
      <title>MSD divulges new KLKB1 inhibitors</title>
      <description>
        <![CDATA[Merck Sharp & Dohme LLC (MSD) has reported new plasma kallikrein (KLKB1) inhibitors potentially useful for the treatment of diabetic macular edema, cancer, hereditary angioedema, uveitis, pancreatitis, arthritis, nephropathy and inflammatory disorders and among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731283</guid>
      <pubDate>Tue, 26 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731283-msd-divulges-new-klkb1-inhibitors</link>
    </item>
    <item>
      <title>Daewoong takes over Turn Bio’s longevity platform from Hanall</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731389</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731389-daewoong-takes-over-turn-bios-longevity-platform-from-hanall</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-aging-time.webp?t=1693406596" type="image/jpeg" medium="image" fileSize="349155">
        <media:title type="plain">DNA double helix with sand hour glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Artificial intelligence agents get ready to take on the scientific method </title>
      <description>
        <![CDATA[There are real world demonstrations of how autonomous artificial intelligence agents are poised to disrupt biomedical research, according to two papers published May 19 in <em>Nature.</em> Each describes an AI system that assists across the piece, from generating hypotheses to designing experiments, analyzing the data and refining hypotheses in the light of new data.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731370</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731370-artificial-intelligence-agents-get-ready-to-take-on-the-scientific-method</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-Agent-illustration.webp?t=1779221352" type="image/jpeg" medium="image" fileSize="188897">
        <media:title type="plain">AI Agent illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Artificial intelligence agents get ready to take on the scientific method </title>
      <description>
        <![CDATA[There are real world demonstrations of how autonomous artificial intelligence agents are poised to disrupt biomedical research, according to two papers published May 19 in <em>Nature.</em> Each describes an AI system that assists across the piece, from generating hypotheses to designing experiments, analyzing the data and refining hypotheses in the light of new data.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731327</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731327-artificial-intelligence-agents-get-ready-to-take-on-the-scientific-method</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-Agent-illustration.webp?t=1779221352" type="image/jpeg" medium="image" fileSize="188897">
        <media:title type="plain">AI Agent illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>IND-enabling studies of adult RPE stem cell product for dry AMD</title>
      <description>
        <![CDATA[Cell replacement therapy is currently being investigated to restore the retinal pigment epithelium (RPE) layer and treat vision decline due to dry age-related macular degeneration (AMD). The Neural Stem Cell Institute and collaborating institutions developed an approach to RPE replacement using an adult RPE stem cell source derived from the RPE layer of donated cadaver eyes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731142</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731142-ind-enabling-studies-of-adult-rpe-stem-cell-product-for-dry-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Senior-eye-exam.webp?t=1686607556" type="image/jpeg" medium="image" fileSize="176885">
        <media:title type="plain">Senior eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>ASGCT 2026: Directed evolution in gene therapy</title>
      <description>
        <![CDATA[Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and delivery vectors. Molecular diversification methods are increasingly sophisticated and are now accelerated by machine learning and AI tools, as showcased at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) held in Boston this week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731119</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731119-asgct-2026-directed-evolution-in-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-and-genome-editing.webp?t=1778858165" type="image/jpeg" medium="image" fileSize="96216">
        <media:title type="plain">DNA and genome editing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>BTX-001 enables single-dose treatment for geographic atrophy</title>
      <description>
        <![CDATA[Researchers from Beacon Therapeutics Holdings Ltd. reported the development of BTX-001, an intravitreal gene therapy designed to target the complement pathway through delivery of a C5 inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731075</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731075-btx-001-enables-single-dose-treatment-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-DNA.webp?t=1621374169" type="image/png" medium="image" fileSize="619372">
        <media:title type="plain">Eye and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific</title>
      <description>
        <![CDATA[Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731224</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731224-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-currency-symbols-and-globe.webp?t=1778527058" type="image/jpeg" medium="image" fileSize="144034">
        <media:title type="plain">Eye, currency symbols and globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific</title>
      <description>
        <![CDATA[Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731193</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731193-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-currency-symbols-and-globe.webp?t=1778527058" type="image/jpeg" medium="image" fileSize="144034">
        <media:title type="plain">Eye, currency symbols and globe</media:title>
      </media:content>
    </item>
    <item>
      <title>OPGx-BEST1 restores BEST1 expression in retinal cells</title>
      <description>
        <![CDATA[Researchers at Opus Genetics Inc. reported the efficacy of OPGx-BEST1, an AVV-based gene therapy developed to deliver a functional BEST1 transgene to retinal pigment epithelium (RPE) cells to re-establish normal BEST1 expression and activity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731014</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731014-opgx-best1-restores-best1-expression-in-retinal-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Test-tube-dropper-research.webp?t=1588878251" type="image/png" medium="image" fileSize="320857">
        <media:title type="plain">Test tube, dropper, DNA illustration </media:title>
      </media:content>
    </item>
    <item>
      <title>Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific</title>
      <description>
        <![CDATA[Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731030</guid>
      <pubDate>Mon, 11 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731030-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-currency-symbols-and-globe.webp?t=1778527058" type="image/jpeg" medium="image" fileSize="144034">
        <media:title type="plain">Eye, currency symbols and globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Bayer buying Perfuse for $300M up front in potential $2.45B deal </title>
      <description>
        <![CDATA[In its first substantial M&A transaction since 2021, Bayer AG is buying Perfuse Therapeutics Inc., a firm that has operated quietly, though it reported positive midstage data last year for PER-001, an endothelin antagonist, in glaucoma and diabetic retinopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730862</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730862-bayer-buying-perfuse-for-300m-up-front-in-potential-245b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-financial-charts.webp?t=1685051887" type="image/jpeg" medium="image" fileSize="207505">
        <media:title type="plain">Eye and financial charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Eyes are first prize for newco Link Biologics</title>
      <description>
        <![CDATA[The classic origin story for a biotech startup is that of a scientist who nurtures his work out of a university and to commercial success. For Link Biologics Ltd. and its TSG6-based pipeline, the story is the other way around; it began with now-CEO Reuben Dawkins meeting University of Manchester scientists Tony Day and Caroline Milner while he was on the lookout for “great science that needs help to make it to patients.” The three are now co-founders of Link, which spun out of the University of Manchester in 2021 and has four programs in three indications, all based on TSG-6 biology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730902</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730902-eyes-are-first-prize-for-newco-link-biologics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-digital-eye.webp?t=1589292031" type="image/png" medium="image" fileSize="615294">
        <media:title type="plain">Rays of light beaming from eye</media:title>
      </media:content>
    </item>
    <item>
      <title>Viridian’s Reveal-2 beats expectations with elegrobart in TED </title>
      <description>
        <![CDATA[Top-line data from the Reveal-2 phase III trial of elegrobart to treat chronic thyroid eye disease (TED) drove Viridian Therapeutics Inc.’s stock up by 33.6%, positioning the company for a BLA filing in the first quarter of 2027. The trial met both primary endpoints at week 24: proptosis responder rate, as measured by exophthalmometry, required for a filing with the U.S. FDA; and the overall responder rate, required for an EMA filing. Doses every four weeks or every eight weeks achieved 50% and 54% PRR, respectively, compared to 15% for placebo. The doses also achieved 47% and 54% ORR vs. 15% for placebo. ORR included those with both proptosis and Clinical Activity Score response, defined as no worsening from baseline in the study eye, without deterioration in the fellow eye.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730847</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730847-viridians-reveal-2-beats-expectations-with-elegrobart-in-ted</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-with-digital-overlay.webp?t=1717017591" type="image/jpeg" medium="image" fileSize="355984">
        <media:title type="plain">Eye with digital overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730787</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730643</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Forsight’s robot-assisted platform to transform cataract surgery</title>
      <description>
        <![CDATA[The first fully robot-assisted cataract surgery recently performed using Forsight Robotics Ltd.’s Jasper platform was not only a “transformative” event and a major “milestone” for the company, but also a “huge step forward for the industry,” Joseph Nathan, co-founder, president and chief medical officer, told <em>BioWorld</em>. With one in two people globally needing cataract surgery and unable to get access to care, robot-assisted platforms hold the potential to increase surgical throughput and broaden access to treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730602</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730602-forsights-robot-assisted-platform-to-transform-cataract-surgery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Joseph-Nathan-co-founder-president-and-chief-medical-officer-Forsight-Robotics-4-23.webp?t=1776975792" type="image/jpeg" medium="image" fileSize="413486">
        <media:title type="plain">Joseph Nathan, co-founder, president, and chief medical officer, Forsight Robotics</media:title>
        <media:description type="plain">Joseph Nathan, co-founder, president and chief medical officer, Forsight Robotics</media:description>
      </media:content>
    </item>
    <item>
      <title>Revenio speeds up growth acquiring Visionix for €290M</title>
      <description>
        <![CDATA[Revenio Group Oyj has agreed to acquire ophthalmic diagnostics company Visionix International SAS for an enterprise value of €290 million (US$339 million) as it looks to become a leading player in the global eye care market. The deal expands Revenio’s offering with a highly complementary product and software portfolio, including optical coherence tomography equipment, an important and growing segment which is new to the company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730279</guid>
      <pubDate>Mon, 13 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730279-revenio-speeds-up-growth-acquiring-visionix-for-290m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Close-up-of-eye-and-vision-test.webp?t=1730493501" type="image/jpeg" medium="image" fileSize="159676">
        <media:title type="plain">Close up of eye and vision test</media:title>
      </media:content>
    </item>
    <item>
      <title>AXL inhibition as therapeutic approach for retinoblastoma</title>
      <description>
        <![CDATA[Researchers from Sun Yat-sen University and collaborators reported the preclinical efficacy of SGI-7079, an AXL inhibitor, in models of retinoblastoma.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730329</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730329-axl-inhibition-as-therapeutic-approach-for-retinoblastoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-supply-vessels.webp?t=1683902294" type="image/jpeg" medium="image" fileSize="254242">
        <media:title type="plain">Art concept for tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>With $80M series D, Life Biosciences advances epigenetic reprogramming  </title>
      <description>
        <![CDATA[Armed with a fully subscribed $80 million series D round, Life Biosciences Inc. is making progress with its lead candidate, ER-100, which is in phase I trials testing its theory on reversing the biological effects of aging via partial epigenetic reprogramming.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730208</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730208-with-80m-series-d-life-biosciences-advances-epigenetic-reprogramming</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-mutation-variation.webp?t=1722524925" type="image/jpeg" medium="image" fileSize="179355">
        <media:title type="plain">Illustration of double helix </media:title>
      </media:content>
    </item>
    <item>
      <title>Smart contact lens delivers adaptative glaucoma therapy</title>
      <description>
        <![CDATA[A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation (TIBI), could enable personalized glaucoma therapy, avoiding poor patient adherence to their prescribed regimen and eliminating the need for bulky electronic devices. Animal models tolerate it well and, although the load is concentrated at the edges of the lens, it is still unknown how it could affect visual acuity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730276</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730276-smart-contact-lens-delivers-adaptative-glaucoma-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-anatomy-and-contact-lens.webp?t=1775678594" type="image/jpeg" medium="image" fileSize="480794">
        <media:title type="plain">Eye anatomy and contact lens</media:title>
      </media:content>
    </item>
    <item>
      <title>Merck Wnt first, Surrozen goes next in AMD, DME </title>
      <description>
        <![CDATA[As advances are made by bustling drug developers at work in the Wingless-related integration site (Wnt) pathway, other research is yielding new discoveries as well. Among the closely watched industry players in Wnt are Boehringer Ingelheim GmbH, Merck & Co. Inc., and Surrozen Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730150</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730150-merck-wnt-first-surrozen-goes-next-in-amd-dme</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Illustration-of-Wnt-signaling-pathway.webp?t=1741386502" type="image/jpeg" medium="image" fileSize="376774">
        <media:title type="plain">Illustration of Wnt signaling pathway</media:title>
      </media:content>
    </item>
    <item>
      <title>Smart contact lens delivers adaptative glaucoma therapy</title>
      <description>
        <![CDATA[A smart polymer contact lens measures intraocular pressure (IOP) in real time and automatically releases medication into the eye when IOP goes beyond a critical limit. This technological advance, developed by scientists at the Terasaki Institute for Biomedical Innovation, could enable personalized glaucoma therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730149</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730149-smart-contact-lens-delivers-adaptative-glaucoma-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-anatomy-and-contact-lens.webp?t=1775678594" type="image/jpeg" medium="image" fileSize="480794">
        <media:title type="plain">Eye anatomy and contact lens</media:title>
      </media:content>
    </item>
    <item>
      <title>Khartis Therapeutics identifies new IGF-1R inhibitors</title>
      <description>
        <![CDATA[Work at Khartis Therapeutics Inc. has led to the discovery of new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors potentially useful for the treatment of thyroid-associated ophthalmopathy (Graves ophthalmopathy), age-related macular degeneration, idiopathic orbital inflammatory disease, cancer and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730198</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730198-khartis-therapeutics-identifies-new-igf-1r-inhibitors</link>
    </item>
    <item>
      <title>LHON updates: Gene therapy progress; idebenone receives US CRL </title>
      <description>
        <![CDATA[Chiesi Group’s idebenone faced a regulatory setback last month after the U.S. FDA issued a complete response letter (CRL) to the company’s NDA for Leber hereditary optic neuropathy (LHON), a rare inherited disorder that causes sudden vision loss.But a chance missed for Chiesi may be an opportunity for gene therapies, including Gensight Biologics SA’s lenadogene nolparvovec (Lumevoq; GS-010).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730074</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730074-lhon-updates-gene-therapy-progress-idebenone-receives-us-crl</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eya-and-DNA-illustration.webp?t=1658513444" type="image/png" medium="image" fileSize="350713">
        <media:title type="plain">Eye and DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730089</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730089-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Highly complementary Biogen pays $5.6B; who’s jealous of Apellis? </title>
      <description>
        <![CDATA[Biogen Inc. hardly blinked at the competition faced by Apellis Pharmaceuticals Inc. as the two companies sealed a deal whereby the former has agreed to acquire all outstanding shares of the latter for $41 each, or about $5.6 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729963</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729963-highly-complementary-biogen-pays-56b-whos-jealous-of-apellis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake-with-charts-maps-data.webp?t=1701801114" type="image/jpeg" medium="image" fileSize="281005">
        <media:title type="plain">Handshake with charts, maps, data</media:title>
      </media:content>
    </item>
    <item>
      <title>Elegrobart star in TED phase III but Viridian shares sacked</title>
      <description>
        <![CDATA[Analysts were sounding pleased and the company intends to go ahead with a regulatory filing, but investors seem to have wanted more from Viridian Therapeutics Inc.’s top-line data from the elegrobart (formerly VRDN-003) Reveal-1 phase III trial in active thyroid eye disease (TED). Viridian shares (NASDAQ:VRDN) closed March 30 at $18.53, down $8.86, or 32%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729946</guid>
      <pubDate>Mon, 30 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729946-elegrobart-star-in-ted-phase-iii-but-viridian-shares-sacked</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-eye1.webp?t=1589292057" type="image/png" medium="image" fileSize="296406">
        <media:title type="plain">Face with digital focus on eye</media:title>
      </media:content>
    </item>
    <item>
      <title>Kodiak’s Zenkuda sparkles in Glow2, BLA filing next</title>
      <description>
        <![CDATA[After previous setbacks with the program, investors largely brushed aside ocular-focused Kodiak Sciences Inc.’s anticipated phase III Glow2 data of tarcocimab tedromer in diabetic retinopathy (DR), so the positive top-line superiority results revealed March 26 caught many by surprise as it sets the company up for an accelerated multi-indication BLA submission.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729899</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729899-kodiaks-zenkuda-sparkles-in-glow2-bla-filing-next</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-wireframe-illustration.webp?t=1688152353" type="image/jpeg" medium="image" fileSize="165854">
        <media:title type="plain">Eye wireframe illustration</media:title>
      </media:content>
    </item>
  </channel>
</rss>
